CUREVAC
the RNA people®

Third Quarter and First Nine Months 2021 Financial Results and Business Update

November 19, 2021

CureVac Speakers

Franz-Werner Haas — Business Update

Chief Executive Officer

Klaus Edvardsen — Program Update

Chief Development Officer

Pierre Kemula — Financial Update

Chief Financial Officer

Mariola Fotin-Mleczek — Q&A Availability

Chief Technology Officer

Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the “company”) contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company’s vaccine and treatment candidates and the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements.

Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Selected Key Developments

Prophylactic Vaccines: Shifting Focus to 2nd-Generation Program

In collaboration with GSK

- Resource re-allocation to accelerate second-generation development
- Withdrawal of first-generation candidate, CVnCoV, from EMA review
- Nature publication of second-generation candidate, CV2CoV, shows similar antibody titers as Comirnaty® in non-human primates

Updating Manufacturing Requirements

- Adjusting capacity demands to second-generation program
- Manufacturing shift from first to second-generation constructs

Oncology: Progressing With Lead Candidate CV8102

- Phase 1 immune profiling data support broad systemic immune activation
- Phase 1 expansion part fully recruited; first data expected H2 2022

Financial Updates

- At-the-market financing implemented for up to $600 million*
- Cash position of €1.06 billion as of September 30, 2021

Molecular Therapy: Showing Impact of mRNA Therapeutic

- mRNA therapeutic shown to reduce liver fibrosis in preclinical model

*Future at-the-market offerings, if any, may be used to conduct sales of CureVac's shares, subject, among others, to future market conditions. There is no certainty that CureVac will be able to use the ATM to raise new capital.

EMA: European Medicines Agency

CureVac Pipeline: A Diversified Portfolio

AREA	PROGRAM	CANDIDATE	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
PROPHYLACTIC VACCINES	1st-Gen COVID-19 Program	1st-Gen candidate: CVnCoV[1)]				
	2nd-Gen COVID-19 Program (gsk)	2nd-Gen candidate: CV2CoV				
		Further 2nd-Gen candidates				
	Infectious Disease Program (gsk)	Influenza				
		Four undisclosed targets				
	Rabies	CV7202				
	Diverse Projects (Bill & Melinda Gates foundation)	Rota, malaria, universal influenza				
ONCOLOGY	Solid tumors[2)]	CV8102				
	Shared neo-antigen	-				
	Tumor Associated Antigens	-				
MOLECULAR THERAPY	Cas9 gene-editing (CRISPR Therapeutics)	CRISPR Therapeutics collaboration				
	Liver Diseases	REBIRTH-Research Center collaboration				
	Ocular Diseases	Sheppens Eye Research Institute collaboration				
	Lung Diseases	Yale collaboration				
	Therapeutic Antibodies (Genmab)	Genmab collaboration				

1) Program discontinued, clinical trials ongoing with safety follow-up times for all trial participants
2) Cutaneous melanoma, adenoid cystic carcinoma, squamous cell carcinoma, squamous cell carcinoma of head and neck

COVID-19 Program Strengthens Broad Infectious Disease Partnership with GSK

COVID-19 PROGRAM

- Broad program of **multiple constructs**
- First construct: **CV2CoV**

Broad Technology Approach
Unmodified mRNA
Modified mRNA

Advanced Vaccine Formats
Multivalent vaccines
Combination vaccines

Flexible Protection
Virus variants

BROAD INFECTIOUS DISEASES PROGRAM

- Includes **5 disease targets** next to COVID-19
- First target disease: **INFLUENZA**
- **Technology expansion** following COVID-19 collaboration

CV2CoV Induces Strong Neutralizing Antibody Titers in Non-Human Primates; Nature Publication*





Neutralizing antibody titers

- Two-dose schedule with 12µg
- CV2CoV: faster onset of immune response
- CV2CoV: 50x higher titers at week 5

Variant cross-neutralizing capacity

- Two-dose schedule with 12µg, week 6
- General reduction of titers due to variants
- CV2CoV: higher titers across all variants

NAb: Neutralizing antibodies

*Barouch *et al.*, Nature, 2021

CV2CoV Neutralizing Antibody Titers in Non-Human Primates Fully Competitive with Licensed mRNA Vaccine; Nature Publication*



- Neutralizing antibodies induced after two vaccinations with CV2CoV or Comirnaty® (Pfizer/BioNTech) highly comparable at **peak immunity at week 5**
- Targeted optimizations of unmodified construct can **significantly improve immunogenicity**
- Relevant data for the use of unmodified mRNA for the **potential of overall technology**

NAb: Neutralizing antibodies

*Barouch *et al.*, Nature, 2021

Oncology: CV8102, Strong Immuno-Modulator Tested in Solid Tumors



CV8102-injected tumors

Mimicking a viral infection of the tumor

- Activation of immune cells
- Antigen release and presentation
- Activation of NK cells and T cells
- Inhibiting tumor growth

Distal, non-injected tumors

System amplification of the immune response

- Inhibiting tumor growth

CV8102

- Single-stranded, non-coding RNA
- Formulated with a carrier peptide
- Activates innate (TLR7/8, RIG-I) and adaptive immune system

PHASE 1 CLINICAL STUDY

Dose-escalation part		Expansion part	
Four solid tumors*		Advanced melanoma	
Single-agent	Anti-PD1 combination	Single-agent	Anti-PD1 combination
33 patients	25 patients	10 patients	30 patients
Fully recruited		Fully recruited	

NK: Natural killer *Head & neck squamous cell carcinoma, cutaneous melanoma, adenoid cystic carcinoma, skin squamous cell carcinoma

CV8102 Induces Promising Clinical Responses in Different Indications

CV8102 SINGLE-AGENT TREATMENT



CV8102 + ANTI-PD-1 COMBINATION TREATMENT



HNSCC: head & neck squamous cell carcinoma; MEL: cutaneous melanoma; ACC: adenoid cystic carcinoma; SCC: skin squamous cell carcinoma

Immune Activation Pattern Supports Local and Systemic Effect of CV8102

Intra-tumoral response: induction of T cells

- Representative tumor biopsy: single-agent patient
- Non-injected tumor in cutaneous melanoma





Sox10⁺
CD3⁺
CD4⁺
CD8⁺
CD3⁺CD4⁺
CD3⁺CD8⁺

Graphic simplified for presentation purposes

System Response: interferon-alpha



System Response: interferon-gamma



Molecular Therapy: mRNA Encoding Key Protein in Liver Function Reduces Cell Damage and Attenuates Fibrosis

Liver fibrosis is characterized by a **decrease in HNF4A levels**[1)]

Optimized mRNA encoding for HNF4A is able to **increase HNF4A levels**

Restoring HNF4A levels **decreases fibrosis induced cell damage**

HNF4A levels



HNF4A levels



ALT levels[2)]



1) Full data available at Journal of Hepatology, Yang *et al*; 2021
2) Graphic simplified for presentation purposes

ALT: Alanine aminotransferase

Adapt Manufacturing Capabilities to Anticipated Demand Going into 2022

STREAMLINING EUROPEAN NETWORK

- Account for pandemic demand peak of 2021 and first half of 2022
- Ongoing alignment of capacity with demand for second-generation vaccine

SHIFTING INTERNAL AND EXTERNAL PRODUCTION FOCUS

- CVnCoV stopped, production shift to second-generation program
- Flexibly address variant specific and modified mRNA constructs

CREATING GREATER PROCESS INDEPENDENCE

- Enhanced in-house formulation capabilities
- Continue GMP IV buildup for commercial-scale manufacturing

Set Up of At-the-Market Facility*

Subject to market conditions, option to offer shares worth up to

$600million

At-the-market Facility

If possible to use the at-the-market tool, **proceeds expected to support**:

Technology transition
from first- to second-generation

Accelerate Momentum
of RNA technology across therapeutic areas

*Future at-the-market offerings, if any, may be used to conduct sales of CureVac's shares, subject, among others, to future market conditions. There is no certainty that CureVac will be able to use the ATM to raise new capital.

Cash and Condensed Consolidated P&L Data

(in € millions)	September 30, 2021 (unaudited)	December 31, 2020
Cash and Cash Equivalents	**1,061.0**	**1,322.6**

	Three months ended September 30,		Nine Month ended September 30,	
(in € millions)	**2021** (unaudited)	**2020** (unaudited)	**2021** (unaudited)	**2020** (unaudited)
Revenue	29.3	5.2	61.8	42.8
Cost of Sales, Operating Expenses & Other Operating Income	-172.4	-41.9	-468.5	-106.0
Operating Result	**-143.1**	**-36.7**	**-406.7**	**-63.2**
Financial Result	-0.4	0.0	-1.2	-9.4
Pre-Tax Loss	**-143.5**	**-36.7**	**-407.9**	**-72.6**

Summary and Highlights

Continued commitment to the global fight against COVID-19, CVnCoV review withdrawn in favor of **advanced candidates** better suited to pandemic and post-pandemic needs

Fully aligned priorities with GSK for broad **infectious disease program** to accelerate development of second-generation mRNA pipeline, including COVID-19

Taking an **unrestricted technology approach** for data-driven best candidate selection; highly relevant preclinical CV2CoV data showed competitiveness of unmodified mRNA approach tested in parallel to modified constructs

Accelerating momentum across all therapeutic areas with promising data in oncology and molecular therapy while leveraging learnings and infrastructure from CVnCoV

CureVac
the RNA people®

Thank you for your attention

CureVac
www.curevac.com